Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism
| dc.contributor.author | Agouridis, A. P. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Tsimihodimos, V. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:29:31Z | |
| dc.date.available | 2015-11-24T19:29:31Z | |
| dc.identifier.issn | 1744-8344 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22975 | |
| dc.rights | Default Licence | - |
| dc.subject | Azetidines/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Humans | en |
| dc.subject | Hyperlipidemias/*drug therapy | en |
| dc.subject | Hypolipidemic Agents/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Lipid Metabolism/drug effects | en |
| dc.title | Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism | en |
| heal.abstract | In this article we discuss the available data on the effects of combined therapy of ezetimibe with agents affecting lipid metabolism other than statins. We consider studies evaluating the effects of combined therapy of ezetimibe with bile acid sequestrants, fenofibrate, niacin, n-3 fatty acids, plant sterols, orlistat, metformin, acarbose and glitazones. Combination of ezetimibe with bile acid sequestrants (especially colesevelam) was shown to have additional effects on lipid parameters in patients with hyperlipidemia. Combination of ezetimibe with fenofibrate may be a good approach to improve the overall lipid profile of patients with mixed hyperlipidemia. The addition of ezetimibe to niacin-based therapy can be useful for high-risk patients with dyslipidemia who are not achieving their assigned treatment goals. For patients who cannot tolerate statins there are useful combinations of ezetimibe with other drugs affecting lipid metabolism. These combinations improve many metabolic parameters, but more trials should be carried out to reach more robust conclusions about their effects on cardiovascular disease prevention. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | 10.1586/erc.11.4 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21438815 | - |
| heal.identifier.secondary | http://www.expert-reviews.com/doi/pdfplus/10.1586/erc.11.4 | - |
| heal.journalName | Expert Rev Cardiovasc Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2011 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.74 KB
- Format:
- Item-specific license agreed upon to submission
- Description: